An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial
European Heart Journal - Cardiovascular Pharmacotherapy · 08.02.2025 · 11 (1) · 34-44
DOI: 10.1093/ehjcvp/pvae075 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 23.10.2024. Verfasst von Ko Yamamoto und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Coronary Artery Disease, Diabetes Mellitus, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Abbott Medical Japan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Safety of aspirin-free strategy immediately after percutaneous coronary intervention (PCI) for cardiovascular events in patients with diabetes was unknown. Methods and results We conducted the prespecified subgroup analysis on diabetes in the STOPDAPT-3 trial, which randomly compared prasugrel (3.75 mg/day) monotherapy (2984 patients) to dual antiplatelet therapy (DAPT) with prasugrel and aspirin (2982 patients) in patients with acute coronary syndrome or high bleeding risk. The co-primary endpoints were major bleeding events (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) at 1 month. Of 5966 study patients, there were 2715 patients (45.5%) with diabetes. Patients with diabetes more often had chronic coronary syndrome, heart failure or cardiogenic shock, and comorbidities than those without. Patients with diabetes compared to those without had higher incidences of major bleeding and cardiovascular events. Regardless of diabetes, the effect of no-aspirin relative to DAPT was not different for the co-primary bleeding (diabetes: 5.05% vs. 5.47%; HR, 0.92; 95%CI, 0.66–1.28 and non-diabetes: 3.99% vs. 4.07%; HR, 0.98; 95%CI, 0.69–1.38; P for interaction = 0.81) and cardiovascular (diabetes: 5.54% vs. 5.15%; HR, 1.08; 95%CI, 0.78–1.49 and non-diabetes: 2.95% vs. 2.47%; HR, 1.20; 95%CI, 0.79–1.82; P for interaction = 0.70) endpoints. The incidences of subacute definite or probable stent thrombosis and any coronary revascularization were higher in the no-aspirin group than in the DAPT group regardless of diabetes.
Conclusions
The effects of an aspirin-free prasugrel monotherapy (3.75 mg/day) relative to DAPT for major bleeding and cardiovascular events were not different regardless of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan.
- Department of Cardiovascular Medicine, Saga University, Saga 849-0937, Japan.
- Department of Cardiology, Hirakata Kohsai Hospital, Hirakata 573-0153, Japan.
- Department of Data Science, Hyogo Medical University, Nishinomiya 663-8501, Japan.
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
- Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni 410-2211, Japan.
ORCID-Profile: Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Tsuyoshi Isawa, Koh Ono, Takeshi Kimura
Förderung
- Abbott Medical Japan
Zitieren
APA
Yamamoto, K., Natsuaki, M., Watanabe, H., Morimoto, T., Obayashi, Y., Nishikawa, R., Ando, K., Suwa, S., Isawa, T., Takenaka, H., Ishikawa, T., Ikari, Y., Kurita, T., Kaitani, K., Sugimoto, A., Ogata, N., Ikuta, A., Hashimoto, K., Ishibashi, Y., …, & Kimura, T. (2025). An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 11(1), 34-44. https://doi.org/10.1093/ehjcvp/pvae075
Vancouver
Yamamoto K, Natsuaki M, Watanabe H, Morimoto T, Obayashi Y, Nishikawa R, et al. An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2025;11(1):34-44. doi:10.1093/ehjcvp/pvae075
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Ko and Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Obayashi, Yuki and Nishikawa, Ryusuke and Ando, Kenji and Suwa, Satoru and Isawa, Tsuyoshi and Takenaka, Hiroyuki and Ishikawa, Tetsuya and Ikari, Yuji and Kurita, Tairo and Kaitani, Kazuaki and Sugimoto, Atsuhiko and Ogata, Nobuhiko and Ikuta, Akihiro and Hashimoto, Katsushi and Ishibashi, Yuki and Masuda, Kazunori and Miyabe, Tomonori and Ono, Koh and Kimura, Takeshi},
title = {An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
volume = {11},
number = {1},
pages = {34--44},
doi = {10.1093/ehjcvp/pvae075}
}
EUVIMED